《癌癥研究與治療》是韓國(guó)癌癥協(xié)會(huì)的一份同行評(píng)審的開放訪問出版物。每季度出版一期，每年出版一冊(cè)。簡(jiǎn)稱為癌癥治療。它接受與實(shí)驗(yàn)和臨床癌癥研究相關(guān)的手稿。受試者包括致癌、腫瘤生物學(xué)、分子腫瘤學(xué)、癌癥遺傳學(xué)、腫瘤免疫學(xué)、流行病學(xué)、預(yù)測(cè)標(biāo)志物和癌癥預(yù)防、病理學(xué)、癌癥診斷、篩查和治療，包括化療、手術(shù)、放射治療、免疫治療、基因治療、多模態(tài)治療和姑息治療。癌癥研究與治療（CRT）由SCI、MEDLine、PubMed、PubMed Central、Koreamed、CrossRef、Chemical Abstracts Service（CAS）、Scopus、Komci和Google Scholar編制索引/跟蹤/覆蓋。

Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; www.thetcr.org) is an Open Access, peer-reviewed journal, published by AME Publishing Company, publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. TCR will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving cancer patients lives. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles. The Official Publication of Society for Translational Cancer Research (STCR),Hong Kong